In a study examining the use of magic mushrooms in Canada, nearly 80% of participants expressed their conviction that psilocybin, the active ingredient in magic mushrooms, should be offered as a medical treatment for patients in distress. Moreover, about two-thirds of the Canadian participants in the same study concurred that psilocybin should be legally accessible for those in need.
Beyond just advocating for increased accessibility to psilocybin, a noteworthy 84.8 percent of participants are of the opinion that the public health system should bear the costs of such treatments. A considerable number of Canadians view psilocybin as a feasible solution, especially for alleviating end-of-life anxiety.
[toc]
Key Findings:
- Citizens of Québec, Ontario, Alberta, and British Columbia perceive psilocybin as a legitimate medical option for managing end-of-life existential anxiety.
- Magic mushrooms are deemed safe for treating existential distress.
- Participants in two double-blind trials reported immediate and sustained benefits, with effects lasting six months or even longer.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals face their mortality. Patients may endure feelings of helplessness, isolation, anxiety, and a loss of meaning and purpose. Such distress is particularly prevalent in patients with life-threatening conditions, potentially leading to thoughts of premature death or suicide.
Individuals grappling with terminal illnesses or significant life changes are the ones most likely to experience this type of distress, which profoundly impacts their mental health and overall life quality.
Existential therapy aims to tackle issues like anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. It often necessitates several sessions and might not work for everyone.
The unpredictability of the effectiveness of such therapy is a primary reason why many individuals seek alternative treatments.
Health Canada’s Perspective on Psilocybin for Treatment Purposes
Over the last two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances in addressing complex mental disorders. Specifically, psilocybin has demonstrated rapid and sustained relief from existential distress in patients nearing life’s end.
Recognizing the possible effectiveness of these suggested hallucinogenic mushrooms, especially when conventional treatments are inadequate, Health Canada revised the Special Access Program in 2022. This revision permits healthcare providers to request controlled substances for their patients.
Canadian Support for Psilocybin Access
A study published in the Palliative Care Journal examines public attitudes on psilocybin-assisted therapy for end-of-life care. The study’s data includes:
| Methodology | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of them had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% view psilocybin-assisted therapy as a legitimate medical option for mitigating end-of-life existential distress. 63.3% think psilocybin should be integrated into medical treatments. 84.8% endorse public health system’s provision of this therapy. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
These findings align with surveys conducted in Canada, England, and Australia. The researchers highlighted that their study is distinctive as it focuses on using psychoactive substances to alleviate existential distress in end-of-life situations.
Why Canadians Support Psilocybin Use
An increasing number of Canadians are accepting the use of psilocybin for treatment, largely due to results from esteemed research institutions. Another factor is the perceived safety of psilocybin mushrooms for easing existential distress. No severe negative health effects, such as multi-organ failure, have been reported by subjects in different studies.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and enduring The benefits of this therapy can last up to six months or longer. The success of this therapy is primarily due to the mystical experiences it induces, which are marked by a sense of unity and deep emotional insight. |
| New York University Trial | 29 patients were randomly selected to either receive psilocybin or the active placebo, niacin | Results from this trial echoed those of the Johns Hopkins study. Participants who were administered psilocybin reported psychological relief and a more positive outlook on life and death. |
| BMC Palliative Care | The study surveyed nineteen participants, including 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist. The objective of the research was to understand palliative care professionals’ perception of existential distress and their opinions on psychedelic therapy as a treatment option. | According to palliative care professionals, psychedelic-assisted therapy (PAT) has the potential to alleviate existential distress. |
Patient Experiences
Scientific research isn’t the only evidence supporting the efficacy of psilocybin. Numerous patient stories further highlight its capacity to improve mental health and overall quality of life.
Journey of Yokoi
Mio Yokoi, a terminal stage 4 pancreatic cancer patient, shares a transformative experience during her assisted therapy. She visualizes herself on a raft, surrounded by nature, in the company of fantastical creatures. This vision instilled a profound sense of the universe’s interconnectedness and support, bringing her immense peace and affirmation.
Despite conventional mental health support, Yokoi continued to struggle with severe anxiety and distress following her diagnosis. Psilocybin therapy helped her reconnect with her body and provided a tangible sense of love and support, significantly improving her emotional and mental health.
Narrative of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. At the time of the study, she was working full-time as an administrative supervisor in healthcare and identified as an atheist. She was also diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in her levels of anxiety, depression, death anxiety, hopelessness, and demoralization. When asked about any alterations in her religious or spiritual beliefs post-therapy, she indicated that the experiences had brought life and significance to her beliefs.
Brenda’s Journey
Within her therapy sessions, Brenda encountered the sensation of death twice. Despite this, she surfaced from the sessions with a newfound acceptance of death, viewing it as an integral part of the cycle of life. The study was recognized as the catalyst for her healing journey from childhood trauma, a sentiment reflected in her data. It was observed that her anxiety and fear of death decreased significantly, while her spirituality increased.
Availability of Magic Mushroom Products in Canada
The accessibility of psilocybin capsules and other products designed to manage existential distress or other mental health concerns may be limited at present. However, reliable online dispensaries can serve as a valuable resource for these products when needed.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and a few adjacent South American countries. | Discovered in Cambodia, particularly around the Angkor Wat Temple. | Linked to the Penis Envy mushrooms, which became popular in the 1970s. |
| Potency | Moderate potency, ideal for beginners. | Equally moderate in potency, perfect for novices. | Extremely potent; suitable for those with moderate to extensive experience. |
| Effects | Leads to a mental buzz, minor disorientation, enhanced color perception, euphoria, spiritual experiences, amplified creativity, and increased focus. | Triggers an invigorating and enduring high, slight visual changes, enhanced creativity, euphoria, a gentle physical high, fractal images, and feelings of joy. | Provokes profound shamanic experiences, vision quests, intense mystical experiences, heightened creativity, focus, social awareness, and mood enhancement. |
Ease End-of-life Discomfort with Psilocybin Products
Existential or end-of-life distress can take a heavy toll on patients nearing the end of their lives. Traditional treatments for this distress can occasionally be inadequate, leading to increased Canadian advocacy for more accessible magic mushrooms within public healthcare. This growing public attention could
We invite regulatory authorities to explore the potential of magic mushrooms as a feasible therapeutic option. Obtain your psychedelics from shroom delivery at Magic Mushrooms Quebec Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
Experiences of patients participating in Psychedelic-assisted therapy (PAT) can greatly differ, and strict adherence to certain procedures and careful preparation are crucial for a positive outcome. Patients are required to undergo a thorough assessment and mental readiness prior to consuming the substance.
- Preparation before the Session: Patients go through a detailed evaluation. The therapist discusses the patient’s goals and expectations to set the intentions for the session. The therapist also explains the possible effects of the process and what the patient should expect during the session.
- The Session: The patient receives a controlled dose of the substance in a session set in a comfortable, distraction-free environment to facilitate relaxation and introspection. The therapist offers ongoing support and guidance throughout this process.
- Post-Session Integration Therapy: This therapy helps the patient in interpreting and assimilating their experiences. Follow-up sessions provide continued support and counselling to reinforce the insights and transformations attained during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by attaching to serotonin receptors, specifically the 5-HT2A receptor. This interaction can cause alterations in perception, mood, and cognition, leading to significant consciousness shifts, emotional discoveries, and new outlooks.
Is psilocybin therapy available to everyone?
Psilocybin therapy is not appropriate for everyone. Patients with particular mental health conditions or existential distress are rigorously screened to rule out those with a past history of psychosis.
Related Articles:
